Analysts Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $10.80

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $8.60.

SANA has been the topic of several research analyst reports. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday, March 18th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Sana Biotechnology in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a research report on Thursday, April 24th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price for the company.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after acquiring an additional 9,359 shares during the last quarter. SCS Capital Management LLC purchased a new position in Sana Biotechnology during the 1st quarter worth $137,000. Woodline Partners LP grew its position in Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after purchasing an additional 90,515 shares during the last quarter. Clearline Capital LP acquired a new position in Sana Biotechnology in the first quarter valued at $690,000. Finally, AQR Capital Management LLC raised its holdings in shares of Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 1.0%

Sana Biotechnology stock opened at $2.87 on Friday. The company has a fifty day simple moving average of $2.17 and a 200-day simple moving average of $2.35. The stock has a market cap of $647.13 million, a P/E ratio of -3.26 and a beta of 1.78. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.40.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. As a group, sell-side analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.